Patients with cancer are generally more prone to infections due to their malignancy, comorbidities, age, or anticancer therapies, but the effects of SARS-CoV-2 in patients with cancer are still unknown. Dai et al. conducted a study in 14 hospitals in Wuhan, China, comparing 105 patients with cancer to 536 age-matched patients without cancer, all of whom were diagnosed with COVID-19. The aim of this study was to report the clinical outcomes of patients with concomitant cancer and COVID-19 infection. Upon admission, all patients had similar signs and symptoms except for a higher prevalence of chest distress in patients with cancer. Patients with COVID-19 and cancer had higher rates of severe events, as well as having at least one severe or critical symptom. Patients with localized cancer experienced similar frequencies of severe events to those observed in patients without cancer. Recent surgery or immunotherapy was associated with a higher risk of severe events, while undergoing recent radiotherapy or chemotherapy was not. No association between immunosuppression and severe outcomes was observed. These findings highlight that patients with cancer may be particularly vulnerable to COVID-19 infection.